Clinical utility of pharmacogenetic testing in compounding pharmacy.

Pharmacists must consider all factors when dosing medication for a patient. Until recently, however, one key piece to this puzzle was missing--genetics. This invisible piece of the puzzle can now be utilized with pharmacogenetic testing. By using pharmacogenetic testing, the compounding pharmacist will be able to better predict disease risk as well as the pharmacodynamic and pharmacokinetic actions of the prescriptions their patients are taking. Pharmacogenetics is poised to become the standard of care that not only physicians are embracing, but pharmacists can utilize to better personalize their patient's needs.

[1]  Mohd Hamid,et al.  Breast Cancer Risk Assessment Tool , 2014 .

[2]  H. Brauch,et al.  Estrogen Metabolism and Exposure in a Genotypic–Phenotypic Model for Breast Cancer Risk Prediction , 2011, Cancer Epidemiology, Biomarkers & Prevention.

[3]  W. Foulkes,et al.  Hereditary breast cancer: new genetic developments, new therapeutic avenues , 2008, Human Genetics.

[4]  M. Pirmohamed,et al.  Pharmacogenetics of warfarin: current status and future challenges , 2007, The Pharmacogenomics Journal.

[5]  J. Russo,et al.  17‐Beta‐Estradiol induces transformation and tumorigenesis in human breast epithelial cells , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[6]  J. Russo,et al.  Estradiol and its metabolites 4‐hydroxyestradiol and 2‐hydroxyestradiol induce mutations in human breast epithelial cells , 2006, International journal of cancer.

[7]  E. Cavalieri,et al.  Mutagenic activity of 4-hydroxyestradiol, but not 2-hydroxyestradiol, in BB rat2 embryonic cells, and the mutational spectrum of 4-hydroxyestradiol. , 2006, Chemical research in toxicology.

[8]  J. Yager,et al.  Estrogen carcinogenesis in breast cancer. , 2006, The New England journal of medicine.

[9]  J. Hirsh,et al.  The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. , 2004, Chest.

[10]  Stephen W Duffy,et al.  A breast cancer prediction model incorporating familial and personal risk factors , 2004, Hereditary Cancer in Clinical Practice.

[11]  M. Gross,et al.  Metabolism and DNA binding studies of 4-hydroxyestradiol and estradiol-3,4-quinone in vitro and in female ACI rat mammary gland in vivo. , 2003, Carcinogenesis.

[12]  E. Cavalieri,et al.  Genotoxic metabolites of estradiol in breast: potential mechanism of estradiol induced carcinogenesis , 2003, The Journal of Steroid Biochemistry and Molecular Biology.

[13]  Jane L Meza,et al.  Relative imbalances in estrogen metabolism and conjugation in breast tissue of women with carcinoma: potential biomarkers of susceptibility to cancer. , 2003, Carcinogenesis.

[14]  M. Pirmohamed.  Pharmacogenetics and pharmacogenomics. , 2001, British journal of clinical pharmacology.

[15]  K. Korach,et al.  Catechol estrogen metabolites and conjugates in mammary tumors and hyperplastic tissue from estrogen receptor-alpha knock-out (ERKO)/Wnt-1 mice: implications for initiation of mammary tumors. , 2001, Carcinogenesis.

[16]  B. Weber,et al.  Assessing the risk of breast cancer. , 2000, The New England journal of medicine.

[17]  J. Liehr,et al.  Induction of uterine adenocarcinoma in CD-1 mice by catechol estrogens. , 2000, Cancer research.

[18]  D. Visscher,et al.  Direct action of estrogen on sequence of progression of human preneoplastic breast disease. , 1998, The American journal of pathology.

[19]  K. Patil,et al.  Molecular origin of cancer: catechol estrogen-3,4-quinones as endogenous tumor initiators. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[20]  N Risch,et al.  Autosomal dominant inheritance of early‐onset breast cancer. Implications for risk prediction , 1994, Cancer.

[21]  M. Gail,et al.  Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. , 1989, Journal of the National Cancer Institute.

[22]  D. G. Hoel,et al.  ‘Hormonal’ risk factors, ‘breast tissue age’ and the age-incidence of breast cancer , 1983, Nature.

[23]  B. Macmahon,et al.  Breast cancer in relation to nursing and menopausal history. , 1960, Journal of the National Cancer Institute.

[24]  U. Klotz.  The Role of Pharmacogenetics in the Metabolism of Antiepileptic Drugs , 2007, Clinical pharmacokinetics.

[25]  William R. Hendee,et al.  To Err is Human: Building a Safer Health System , 2001 .

[26]  Fritz F. Parl,et al.  Estrogens, Estrogen Receptor, and Breast Cancer , 2000 .